Lyc.HCL holds promise as a potential therapeutic agent for ESCC as it targets TRIM22, a critical molecule, and modulates the JAK2/STAT3 and ERK signaling pathways. This evidence concerns the gene STAT3 and esophageal squamous cell carcinoma.